‘Dual’ peptidyl-oligonucleotide conjugates: Role of conformational flexibility in catalytic cleavage of RNA
Open Access
- 1 January 2017
- journal article
- Published by Elsevier in Biomaterials
- Vol. 112, 44-61
Abstract
No abstract availableKeywords
Funding Information
- Russian Science Foundation (14-44-00068)
- EPSRC (EP/G017905/1)
- Collaborative Research Framework Agreement with SOLVAY
This publication has 69 references indexed in Scilit:
- Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic AgentsJournal of Medicinal Chemistry, 2015
- Clinical evaluation of microRNA expression profiling in non small cell lung cancerLung Cancer, 2013
- MicroRNAs and cardiovascular diseasesThe FEBS Journal, 2011
- Pervasive roles of microRNAs in cardiovascular biologyNature, 2011
- MicroRNAs (miRNAs) in Neurodegenerative DiseasesBrain Pathology, 2008
- MicroRNA Signatures in Human Ovarian CancerCancer Research, 2007
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic DrugsAccounts of Chemical Research, 2007
- MicroRNA Gene Expression Deregulation in Human Breast CancerCancer Research, 2005
- Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancerWorld Journal of Urology, 2005
- Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapyThe Prostate, 2002